{
    "clinical_study": {
        "@rank": "164942", 
        "acronym": "KD in obesity", 
        "arm_group": [
            {
                "arm_group_label": "Ketogenic diet, lifestyle counseling", 
                "arm_group_type": "Active Comparator", 
                "description": "ketogenic diet consisted of 3:1[fat]:[protein+carbohydrate] weight ratio with 1600kcal restriction."
            }, 
            {
                "arm_group_label": "Orlistat, Lifestyle counseling", 
                "arm_group_type": "Active Comparator", 
                "description": "Orlistat 120 mg TID, standardized diet and lifestyle-modification counseling based on the LEARN (Life, Exercise, Attitudes, Relationships,and Nutrition) program with recommended caloric goal of 1600 kcal/day."
            }, 
            {
                "arm_group_label": "Standartized diet, Lifestyle counseling", 
                "arm_group_type": "Active Comparator", 
                "description": "Standardized diet and lifestyle-modification counseling based on the LEARN (Lifestyle, Exercise, Attitudes, Relationship, Nutrition) program with recommended caloric goal of 1600kcal/day."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the efficacy and safety of ketogenic diet (KD)\n      treatment of (i) obesity, (ii) type 2 diabetes mellitus and (iii) obstructive sleep apnea\n      (OSA) in patients with obesity and Type 2 DM and in patients with obesity and/or OSA. This\n      will be a randomized, open-label three arm controlled study comparing weight loss in obese\n      participants with type 2 diabetes and/or obstructive sleep apnea treated for 9 months with\n      3:1 [fat]:[protein+carbohydrate] ratio, 1600 kcal/day diet (Group A) with weight loss in\n      participants treated with orlistat 120 mg TID and lifestyle intervention consisting of\n      dietary advice, recommended caloric goal of 1600 kcal/day (Group B), and in participants\n      treated with only lifestyle intervention consisting of dietary advice, recommended caloric\n      goal of 1600 kcal/day (Group C)."
        }, 
        "brief_title": "Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Obesity", 
            "Diabetes", 
            "Obstructive Sleep Apnea"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Apnea", 
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Obesity", 
                "Sleep Apnea Syndromes", 
                "Sleep Apnea, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study sample  will be randomized into three treatment arms, KD (Group A, n=50), Orlistat\n      120 mg TID (Group B, n=50) and dietary and lifestyle counseling (Group C, n=50) in a 1:1:1\n      ratio. Each arm will include 100% participants with obesity and co-morbid type 2 DM and 50%\n      participants with co-morbid OSA.  Randomization will be stratified for diabetic status."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age 18-70\n\n          -  ability and willingness to signed informed consent form\n\n          -  BMI more than 30kg/m2, with type 2 DM and/or OSA\n\n          -  For diabetic participants, stable hypoglycemic medications for at least 2 months\n\n          -  For participants with OSA, previously documented polysomnogram with    apnea/hypopnea\n             index (AHI)>15/h.\n\n        Exclusion Criteria:\n\n          -  BMI change of +/- 3.0 kg/m2 of baseline BMI within past 12 months.\n\n          -  History of bariatric surgery \u2264 3 years prior to enrollment.\n\n          -  Any systemic illness or unstable medical condition that might pose       additional\n             risk, including: cardiac, unstable metabolic or endocrine disturbances, renal or\n             liver disease, past history of renal calculi, hyperuricemia, hypercalcemia,\n             mitochondrial disease, known disorder of fatty acid metabolism, porphyria, and active\n             systemic cancer.\n\n          -  History of uncontrolled hyperlipidemia\n\n          -  For participants with DM, change in the dose or type of hypoglycemic treatment within\n             2 months prior to enrollment.\n\n          -  Psychosis within six months of enrollment, evidenced by treatment with anti-psychotic\n             medications with recent medication initiation or dose increase.\n\n          -  Active drug or alcohol dependence or any other factors that, in the opinion of the\n             site investigators would interfere with adherence to study requirements;\n\n          -  History of hyperthyroidism\n\n          -  History of glaucoma\n\n          -  History of cerebrovascular disease or unstable heart disease within 6 months of\n             enrollment\n\n          -  Pregnancy\n\n          -  Use of any investigational drugs within 3 months of enrollment.\n\n          -  Inability or unwillingness of subject to give written informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02069197", 
            "org_study_id": "maes 004"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ketogenic diet, lifestyle counseling", 
                "description": "ketogenic diet will consist of 3:1[fat]:[protein+carbohydrate]weight ratio with 1600 kcal restriction. Diet will last 9 months.", 
                "intervention_name": "Ketogenic diet", 
                "intervention_type": "Other", 
                "other_name": "high fat, low protein, low carbohydrate diet"
            }, 
            {
                "arm_group_label": "Orlistat, Lifestyle counseling", 
                "description": "Orlistat 120 mg TID for 9 months; life style intervention with recommended caloric goal of 1600 kcal/day.", 
                "intervention_name": "Orlistat", 
                "intervention_type": "Drug", 
                "other_name": "tetrahydrolipstatin"
            }, 
            {
                "arm_group_label": "Standartized diet, Lifestyle counseling", 
                "description": "Standardized diet treatment for 9 months with recommended caloric goal of 1600kcal/day.", 
                "intervention_name": "Standardized diet", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Orlistat"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ketogenic diet", 
            "obesity", 
            "diabetes", 
            "obstructive sleep apnea"
        ], 
        "lastchanged_date": "February 19, 2014", 
        "location": {
            "contact": {
                "email": "tyrlikovai@epilepsydc.com", 
                "last_name": "Ivana Tyrlikova, MD", 
                "phone": "301-530-9744"
            }, 
            "contact_backup": {
                "email": "barbera@epilepsydc.com", 
                "last_name": "Arcady Barber, MSCN", 
                "phone": "301-530-9744"
            }, 
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20817"
                }, 
                "name": "Mid-Atlantic Epilepsy and Sleep Center, LLC"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Evaluation of Efficacy and Safety of Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea.", 
        "overall_contact": {
            "email": "tyrlikovai@epilepsydc.com", 
            "last_name": "Ivana Tyrlikova, MD", 
            "phone": "301-530-9744"
        }, 
        "overall_contact_backup": {
            "email": "barbera@epilepsydc.com", 
            "last_name": "Arcady Barber, MSCN", 
            "phone": "301-530-9744"
        }, 
        "overall_official": {
            "affiliation": "Mid-Atlantic Epilepsy and Sleep center", 
            "last_name": "Pavel Klein, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The change of weight and the BMI(body mass index) will be calculated.", 
            "measure": "Change of body mass index from baseline in 9 months period", 
            "safety_issue": "No", 
            "time_frame": "9 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02069197"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mid-Atlantic Epilepsy and Sleep Center, LLC", 
            "investigator_full_name": "Pavel Klein", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "HbA1C, fasting serum glucose insulin and leptin levels and fasting lipid levels", 
                "measure": "Change from baseline in glucose blood level in patients with diabetes mellitus in 9 months.", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }, 
            {
                "description": "For participants with OSA, secondary outcome will include polysomnogram-derived apnea/hypopnea index.\nLevel of alertness will be evaluated with Epworth Sleepiness Scale.", 
                "measure": "Change of apnea/hypopnea index in patients with obstructive sleep apnea in patients with obesity", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }, 
            {
                "description": "Evaluate in serum levels of beta-hydroxybutyrate, glucose, electrolytes, renal and liver functions, uric acid, HB1C1, serum lipid profile, insulin and leptin levels, CRP.", 
                "measure": "To evaluate safety of ketogenic diet as a treatment of obesity.", 
                "safety_issue": "Yes", 
                "time_frame": "9 months"
            }
        ], 
        "source": "Mid-Atlantic Epilepsy and Sleep Center, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mid-Atlantic Epilepsy and Sleep Center, LLC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}